Investigating Treatment of Primary Axillary Hyperhidrosis With a Topical Retrometabolic Anticholinergic Drug

Main Article Content

Nicholas Bodor
Adam Friedman
Stacy Smith
James Del Rosso
Janet Dubois
Adelaide Herbert
Tory Sullivan
Zakiya Rice
Joe Gorlick
Leon Kircik
Lawrence Green
Brandon Kirsch
Deepak Chadha

Keywords

primary axillary hyperhidrosis, retrometabolic anticholingeric drug

Abstract

N/A

References

1 Bodor N, Buchwald P. Retrometabolic Drug Design and Targeting. Wiley; 2013.

2 Ji F, Wu W, Dai X, et al. Synthesis and pharmacological effects of new, N-substituted soft anticholinergics based on glycopyrrolate. J Pharm
Pharmacol. 2005;57(11):1427-1435. doi:10.1211/jpp.57.11.0008

3 Tóth-Sarudy E, Tóth G, Pallagi I, et al. Preparation and biological effects of pure stereoisomeric novel soft anticholinergics. Pharm. 2006;61(2):90-96.

4 Samir A, Ohura K, Bodor N, Imai T. Identification of Major Esterase Involved in Hydrolysis of Soft Anticholinergic (2R3’R-SGM) Designed From
Glycopyrrolate in Human and Rat Tissues. J Pharm Sci. 2019;108(8):2791-2797. doi:10.1016/j.xphs.2019.03.030

5 Kirsch B. An Open-Label, Repeat-Dose, Maximum-Use Study to Evaluate the Pharmacokinetics of Sofpironium Bromide Gel, 15% Topically Applied in Subjects with Primary Axillary Hyperhidrosis (Study BBI-4000-CL-102). Presented at the: Fall Clinical; November 29, 2020; Las Vegas, Nevada

Most read articles by the same author(s)

<< < 3 4 5 6 7 8